The information contained on this website is only a summary. You may download a copy of the full Notice by clicking
. Since this website
is just a summary, you should review the Notice for additional details. Your rights may be affected by a proposed settlement in a class action
lawsuit regarding the prices paid for generic Nexium and brand and generic Diovan and Valcyte by third-party payors filed against Defendants
Sun Pharmaceutical Industries, Ltd. and Ranbaxy, Inc. (“Ranbaxy”). The case name is In Re Ranbaxy Generic Drug Application Antitrust Litigation,
MDL No. 2878, Master File No. 19-md-02878-NMG (D. Mass.) (the “Lawsuit”). The Lawsuit, which is pending in the District of Massachusetts,
alleges Defendants engaged in a scheme, in violation of state antitrust, state consumer protection, and federal racketeering laws, involving
misrepresentations to the FDA in connection with pursuing tentative approvals for abbreviated new drug applications, which resulted in delayed
market launch of generic versions of Nexium, Diovan, and Valcyte. As a result, the Lawsuit alleges that the End-Payor Classes paid or
reimbursed for the at-issue drugs at prices that were higher than they would have otherwise been. Defendants deny any wrongdoing.
The Court has preliminarily approved the proposed settlement between the End-Payor Classes and Ranbaxy (the “Settlement”). The proposed
Settlement will provide for the payment of $145 million (the “Settlement Fund”) to resolve the End-Payor Classes’ claims against Ranbaxy.
The full text of the proposed Settlement Agreement, which is dated April 8, 2022, is on the Court Documents page of this website.